Products
Telbivudine is commercially available in the form of film-coated tablets (Sebivo). It has been approved in many countries since 2006. The solution has been off the market since 2012.
Structure and properties
Telbivudine (C10H14N2O5, Mr = 242.2 g/mol) is a thymidine analog and a prodrug that is biotransformed in cells to the active metabolite telbivudine-5-triphosphate. It exists as a white to yellowish powder that is sparingly soluble in water.
Effects
Telbivudine (ATC J05AF11) has antiviral properties. The effects are due to inhibition of viral HBV DNA polymerase (reverse transcriptase). This prevents viral DNA synthesis and viral replication.
Indications
For the treatment of chronic hepatitis B when there is evidence of viral replication and active liver inflammation.
Dosage
According to the SmPC. Tablets are taken once daily, independent of meals.
Contraindications
- Hypersensitivity
- Combination with pegylated interferon alfa-2a
For complete precautions, see the drug label.
Adverse effects
The most common possible adverse effects include dizziness, headache, diarrhea, nausea, and skin rash.
